Endo shutters a pain program following trial failure

There will be no third act for Endo's pain drug partnership with Grunenthal. Endo had originally signed on to the pact in early 2009, gaining U.S. marketing rights to axomadol. But earlier this summer investigators reported the disappointing news that the drug had failed a mid-stage study, and this morning the biotech company said it will shutter the program and dump the collaboration. Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.